Astex Pharmaceuticals

Astex uses its fragment based drug discovery technology to identify and develop new medicines, primarily for the treatment of cancer and antiviral diseases. The company has a number of internally developed therapeutic candidates in clinical trials. Astex merged with SuperGen in July 2011 and was acquired by Otsuka Pharma for $860 million in September 2013.